Results 11 to 20 of about 18,898 (135)

Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial

Diabetology & Metabolic Syndrome, 2021
Background Glucagon-like peptide-1 receptor (GLP-1R) activation may improve myocardial performance in the context of ischaemia, independent of glycaemic control, in individuals with and without type 2 diabetes mellitus.
Aung Myat, Simon R. Redwood, Satpal Arri, Bernard J. Gersh, Deepak L. Bhatt, Michael S. Marber   +5 more
doaj   +1 more source

Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. [PDF]

PLoS ONE, 2015
Glucagon-like peptide-1 (GLP-1) receptor agonists potentiate glucose-induced insulin secretion. In addition, they have been reported to increase pancreatic beta cell mass in diabetic rodents. However, the precise mode of action of GLP-1 receptor agonists
Kanako Tamura, Kohtaro Minami, Maya Kudo, Keisuke Iemoto, Harumi Takahashi, Susumu Seino   +5 more
doaj   +1 more source

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj  

Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

BMC Endocrine Disorders, 2022
Background The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients.
Niroj Mali, Feng Su, Jie Ge, Wen Xing Fan, Jing Zhang, Jingyuan Ma   +5 more
doaj   +1 more source

Liraglutide Attenuates Hepatic Ischemia–Reperfusion Injury by Modulating Macrophage Polarization

Frontiers in Immunology, 2022
Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat type 2 diabetes and obesity ...
Shang-Lin Li, Shang-Lin Li, Zhi-Min Wang, Cong Xu, Cong Xu, Fu-Heng Che, Fu-Heng Che, Xiao-Fan Hu, Xiao-Fan Hu, Rui Cao, Rui Cao, Ya-Nan Xie, Ya-Nan Xie, Yang Qiu, Yang Qiu, Hui-Bo Shi, Hui-Bo Shi, Bin Liu, Bin Liu, Chen Dai, Chen Dai, Jun Yang, Jun Yang   +22 more
doaj   +1 more source

Effects of liraglutide on ANP secretion and cardiac dynamics

Endocrine Connections, 2023
To observe the effects of liraglutide (analog of glucagon-like peptide 1 (GLP-1)) on atrial natriuretic peptide (ANP) secretion and atrial dynamics, an ex vivo isolated rat atrial perfusion model was used to determine atrial ANP secretion and pulse ...
Shenghe Luo, Yunhui Zuo, Xiaotian Cui, Meiping Zhang, Honghua Jin, Lan Hong   +5 more
doaj   +1 more source

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota

Frontiers in Endocrinology, 2018
In addition to improving glucose metabolism, liraglutide, a glucagon-like peptide-1 receptor agonist, has weight-loss effects. The underlying mechanisms are not completely understood.
Li Zhao, Yi Chen, Fangzhen Xia, Buatikamu Abudukerimu, Wen Zhang, Yuyu Guo, Ningjian Wang, Yingli Lu   +7 more
doaj   +1 more source

Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.

PLoS ONE, 2014
The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD).
Takeshi Osonoi, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Daisuke Tsujino, Rimei Nishimura, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

Molecular Medicine, 2023
Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation,
Tingli Guo, Wenhui Yan, Xin Cui, Na Liu, Xiaotong Wei, Yuzhuo Sun, KeXin Fan, Jieyun Liu, Yuanyuan Zhu, Zhuanzhuan Wang, Yilei Zhang, Lina Chen   +11 more
doaj   +1 more source

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies

Scientific Reports, 2017
Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties.
Fernanda Cristina de Mesquita, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Raquel Maeso-Díaz, Sergi Vila, Diana Hide, Martí Ortega-Ribera, José Luís Rosa, Juan Carlos García-Pagán, Jaime Bosch, Jarbas Rodrigues de Oliveira, Jordi Gracia-Sancho   +11 more
doaj   +1 more source